LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

Harvard Bioscience Inc

Gesloten

SectorGezondheidszorg

0.66 3.13

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.63

Max

0.73

Belangrijke statistieken

By Trading Economics

Inkomsten

1.1M

-1.2M

Verkoop

141K

21M

Winstmarge

-5.978

Werknemers

330

EBITDA

42K

197K

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+203.03% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

321K

26M

Vorige openingsprijs

-2.47

Vorige sluitingsprijs

0.66

Nieuwssentiment

By Acuity

50%

50%

185 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Harvard Bioscience Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 nov 2025, 18:59 UTC

Belangrijke Marktbewegers

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 nov 2025, 23:40 UTC

Marktinformatie

Gold Consolidates Amid Mixed Signals -- Market Talk

17 nov 2025, 23:34 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 nov 2025, 22:58 UTC

Marktinformatie

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 nov 2025, 22:46 UTC

Marktinformatie

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 nov 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 nov 2025, 22:02 UTC

Winsten

Trip.com Group 3Q Rev $2.6B >TCOM

17 nov 2025, 22:02 UTC

Winsten

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 nov 2025, 22:02 UTC

Winsten

Trip.com Group 3Q EPS $4.02 >TCOM

17 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 nov 2025, 21:40 UTC

Winsten

James Hardie Industries 2Q Adj EPS 26c >JHX

17 nov 2025, 21:40 UTC

Winsten

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 nov 2025, 21:39 UTC

Winsten

James Hardie Industries 2Q Sales $1.29B >JHX

17 nov 2025, 21:38 UTC

Winsten
Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 21:38 UTC

Winsten

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 nov 2025, 21:10 UTC

Winsten

XP Inc. 3Q EPS BRL2.47 >XP

17 nov 2025, 21:10 UTC

Winsten

XP Inc. 3Q Rev BRL4.67B >XP

17 nov 2025, 20:20 UTC

Marktinformatie

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 nov 2025, 20:12 UTC

Marktinformatie

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 nov 2025, 20:12 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 nov 2025, 20:09 UTC

Marktinformatie

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 nov 2025, 19:29 UTC

Marktinformatie

Gold Slide Continues to Start Week -- Market Talk

17 nov 2025, 19:16 UTC

Winsten
Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 18:20 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 nov 2025, 16:45 UTC

Acquisities, Fusies, Overnames

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 nov 2025, 16:16 UTC

Winsten
Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 16:15 UTC

Winsten

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 nov 2025, 15:40 UTC

Acquisities, Fusies, Overnames

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 nov 2025, 15:22 UTC

Acquisities, Fusies, Overnames

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 nov 2025, 15:19 UTC

Marktinformatie

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Peer Vergelijking

Prijswijziging

Harvard Bioscience Inc Prognose

Koersdoel

By TipRanks

203.03% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2 USD  203.03%

Hoogste 2 USD

Laagste 2 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Harvard Bioscience Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technische score

By Trading Central

0.3 / 0.3401Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

No Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

185 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat